Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial

Yanhong Deng, Pan Chi, Ping Lan, Lei Wang, Weiqing Chen, Long Cui, Daoda Chen, Jie Cao, Hongbo Wei, Xiang Peng, Zonghai Huang, Guanfu Cai, Ren Zhao, Zhongcheng Huang, Lin Xu, Hongfeng Zhou, Yisheng Wei, Hao Zhang, Jian Zheng, Yan Huang, Zhiyang Zhou, Yue Cai, Liang Kang, Meijin Huang, Xiaojian Wu, Junsheng Peng, Donglin Ren, Jianping Wang, Yanhong Deng, Pan Chi, Ping Lan, Lei Wang, Weiqing Chen, Long Cui, Daoda Chen, Jie Cao, Hongbo Wei, Xiang Peng, Zonghai Huang, Guanfu Cai, Ren Zhao, Zhongcheng Huang, Lin Xu, Hongfeng Zhou, Yisheng Wei, Hao Zhang, Jian Zheng, Yan Huang, Zhiyang Zhou, Yue Cai, Liang Kang, Meijin Huang, Xiaojian Wu, Junsheng Peng, Donglin Ren, Jianping Wang

Abstract

Purpose: In the multicenter, open-label, phase III FOWARC trial, modified infusional fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus radiotherapy resulted in a higher pathologic complete response rate than fluorouracil plus radiotherapy in Chinese patients with locally advanced rectal cancer. Here, we report the final results.

Methods: Adults ages 18 to 75 years with stage II/III rectal cancer were randomly assigned (1:1:1) to five cycles of infusional fluorouracil (leucovorin 400 mg/m2, fluorouracil 400 mg/m2, and fluorouracil 2.4 g/m2 over 48 hours) plus radiotherapy (46.0 to 50.4 Gy delivered in 23 to 25 fractions during cycles 2 to 4) followed by surgery and seven cycles of infusional fluorouracil, the same treatment plus intravenous oxaliplatin 85 mg/m2 on day 1 of each cycle (mFOLFOX6), or four to six cycles of mFOLFOX6 followed by surgery and six to eight cycles of mFOLFOX6. The primary end point was 3-year disease-free survival (DFS).

Results: In total, 495 patients were randomly assigned to treatment. After a median follow-up of 45.2 months, DFS events were reported in 46, 39, and 46 patients in the fluorouracil plus radiotherapy, mFOLFOX6 plus radiotherapy, and mFOLFOX6 arms. In each arm, the probability of 3-year DFS was 72.9%, 77.2%, and 73.5% (P = .709 by the log-rank test), the 3-year probability of local recurrence after R0/1 resection was 8.0%, 7.0%, and 8.3% (P = .873 by the log-rank test), and the 3-year overall survival rate was 91.3%, 89.1%, and 90.7% (P = .971 by log-rank test), respectively.

Conclusion: mFOLFOX6, with or without radiation, did not significantly improve 3-year DFS versus fluorouracil with radiation in patients with locally advanced rectal cancer. No significant difference in outcomes was found between mFOLFOX6 without radiotherapy and fluorouracil with radiotherapy, which requires additional investigation of the role of radiotherapy in these regimens.

Trial registration: ClinicalTrials.gov NCT01211210.

Figures

FIG 1.
FIG 1.
Trial profile. mFOLFOX6, modified infusional fluorouracil, leucovorin, and oxaliplatin; PP, per protocol. (*) excluded from PP analysis. (†) 8 patients received radiation.
FIG 2.
FIG 2.
Kaplan-Meier estimates of (A) disease-free survival (DFS), (B) locoregional recurrence after R0/1 resection, and (C) overall survival (OS) in the intention-to-treat population. FU, fluorouracil; HR, hazard ratio; mFOLFOX6, modified infusional fluorouracil, leucovorin, and oxaliplatin; RT, radiotherapy.
FIG 3.
FIG 3.
Multivariable analysis of the effects of prognostic factors on (A) 3-year disease-free survival and (B) locoregional recurrence. CEA, carcinoembryonic antigen; FU, fluorouracil; mFOLFOX6, modified infusional fluorouracil, leucovorin, and oxaliplatin; OR, odds ratio; RT, radiotherapy.
FIG A1.
FIG A1.
Kaplan-Meier estimates of disease-free survival (DFS) in the per-protocol population, which included 445 patients who underwent surgery. FU, fluorouracil; HR, hazard ratio; mFOLFOX6, modified infusional fluorouracil, leucovorin, and oxaliplatin; RT, radiotherapy; SD, standard deviation.
FIG A2.
FIG A2.
Kaplan-Meier estimates of locoregional recurrence in the per-protocol population, which included 445 patients who underwent surgery. FU, fluorouracil; HR, hazard ratio; mFOLFOX6, modified infusional fluorouracil, leucovorin, and oxaliplatin; RT, radiotherapy; SD, standard deviation.
FIG A3.
FIG A3.
Kaplan-Meier estimates of overall survival (OS) in the per-protocol population, which included 445 patients who underwent surgery. FU, fluorouracil; HR, hazard ratio; mFOLFOX6, modified infusional fluorouracil, leucovorin, and oxaliplatin; RT, radiotherapy; SD, standard deviation.

References

    1. Benson AB, III, Venook AP, Al-Hawary MM, et al. Rectal cancer, version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16:874–901.
    1. Gérard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: Results of FFCD 9203. J Clin Oncol. 2006;24:4620–4625.
    1. De Caluwé L, Van Nieuwenhove Y, Ceelen WP. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst Rev. 2013;(2):CD006041.
    1. McCarthy K, Pearson K, Fulton R, et al. Pre-operative chemoradiation for non-metastatic locally advanced rectal cancer. Cochrane Database Syst Rev. 2012;12:CD008368.
    1. Rahbari NN, Elbers H, Askoxylakis V, et al. Neoadjuvant radiotherapy for rectal cancer: Meta-analysis of randomized controlled trials. Ann Surg Oncol. 2013;20:4169–4182.
    1. Aschele C, Cionini L, Lonardi S, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: Pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011;29:2773–2780.
    1. Allegra CJ, Yothers G, O’Connell MJ, et al. Neoadjuvant 5-FU or capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: A phase III randomized clinical trial. J Natl Cancer Inst. 2015;107:djv248.
    1. Azria D, Doyen J, Jarlier M, et al. Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer. Ann Oncol. 2017;28:2436–2442.
    1. Rödel C, Graeven U, Fietkau R, et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): Final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015;16:979–989.
    1. Rödel C, Liersch T, Becker H, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: Initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012;13:679–687.
    1. Peeters KC, van de Velde CJ, Leer JW, et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: Increased bowel dysfunction in irradiated patients–a Dutch colorectal cancer group study. J Clin Oncol. 2005;23:6199–6206.
    1. Lange MM, den Dulk M, Bossema ER, et al. Risk factors for faecal incontinence after rectal cancer treatment. Br J Surg. 2007;94:1278–1284.
    1. Bruheim K, Guren MG, Skovlund E, et al. Late side effects and quality of life after radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys. 2010;76:1005–1011.
    1. Jalil O, Claydon L, Arulampalam T. Review of neoadjuvant chemotherapy alone in locally advanced rectal cancer. J Gastrointest Cancer. 2015;46:219–236.
    1. Deng Y, Chi P, Lan P, et al. Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: Initial results of the Chinese FOWARC multicenter, open-label, randomized three-arm phase III trial. J Clin Oncol. 2016;34:3300–3307.
    1. Ryan R, Gibbons D, Hyland JM, et al. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology. 2005;47:141–146.
    1. Zheng J, Feng X, Hu W, et al. Systematic review and meta-analysis of preoperative chemoradiotherapy with or without oxaliplatin in locally advanced rectal cancer. Medicine (Baltimore) 2017;96:e6487.
    1. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343–2351.
    1. Lefevre JH, Mineur L, Cachanado M, et al: Does a longer waiting period after neoadjuvant radiochemotherapy improve the oncological prognosis of rectal cancer?: Three-year follow-up results of the GRECCAR-6 randomized multicenter trial. J Clin Oncol 37, 2019 (suppl; abstr 483)
    1. Gérard JP, Azria D, Gourgou-Bourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: Results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol. 2010;28:1638–1644.
    1. Schmoll H-J, Haustermans K, Price T, et al: Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: Disease-free survival results at interim analysis. Proc Am Soc Clin Oncol 32:3501, 2014.
    1. Jiao D, Zhang R, Gong Z, et al. Fluorouracil-based preoperative chemoradiotherapy with or without oxaliplatin for stage II/III rectal cancer: A 3-year follow-up study. Chin J Cancer Res. 2015;27:588–596.
    1. Bernier L, Balyasnikova S, Tait D, et al. Watch-and-wait as a therapeutic strategy in rectal cancer. Curr Colorectal Cancer Rep. 2018;14:37–55.
    1. Kim CH, Lee SY, Kim HR, et al. Prognostic effect of pretreatment serum carcinoembryonic antigen level: A useful tool for prediction of distant metastasis in locally advanced rectal cancer following neoadjuvant chemoradiotherapy and total mesorectal excision. Medicine (Baltimore) 2015;94:e1291.
    1. Lee JH, Kim SH, Jang HS, et al. Preoperative elevation of carcinoembryonic antigen predicts poor tumor response and frequent distant recurrence for patients with rectal cancer who receive preoperative chemoradiotherapy and total mesorectal excision: A multi-institutional analysis in an Asian population. Int J Colorectal Dis. 2013;28:511–517.
    1. Yang KL, Yang SH, Liang WY, et al. Carcinoembryonic antigen (CEA) level, CEA ratio, and treatment outcome of rectal cancer patients receiving pre-operative chemoradiation and surgery. Radiat Oncol. 2013;8:43.
    1. Sung S, Son SH, Kay CS, et al. Prognosis can be predicted more accurately using pre- and postchemoradiotherapy carcinoembryonic antigen levels compared to only prechemoradiotherapy carcinoembryonic antigen level in locally advanced rectal cancer patients who received neoadjuvant chemoradiotherapy. Medicine (Baltimore) 2016;95:e2965.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel